IP Library Granted Patent US 10,172,897
Granted Patent B2
US 10,172,897 · App. 15/951,154 · Granted Jan 8, 2019

Enhanced smokable therapeutic cannabis product and method for making same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,172,897
App. No.
15/951,154
Granted
Jan 8, 2019
Kind
B2
Abstract

An enhanced smokable cannabis -based product produced by separating hash resin from plant material of the cannabis plant, pressing the hash resin to expel oil, leaving spent hash resin, extracting further cannabinoids from the spent hash resin using MCT oil, enriching the extracted oil with a formulation comprising at least purified-myrcene, and spraying the enriched oil onto dried smokable cannabis plant matter.

Claims (15)

1. A method of preparing an enhanced smokable therapeutic cannabis product, the method comprising the steps of:

(a) separating hash resin from plant material of a cannabis plant;

(b) pressing the hash resin to expel oil, leaving spent hash resin;

(c) extracting further cannabinoids from the spent hash resin using medium chain triglyceride oil;

(d) enriching the extracted oil with a formulation comprising at least purified β-myrcene; and

(e) spraying the enriched oil onto dried smokable cannabis plant matter; wherein the formulation comprises at least 5% w/w β-myrcene, between 10% w/w and 20% w/w cannabinol (CBN), and at least 5% w/w pinene.

2. The method of claim 1 , further comprising the step of wrapping the dried smokable plant matter into a conical smokable product after spraying.

3. The method of claim 1 , wherein the formulation comprises at least 25% by weight of purified THC.

4. The method of claim 1 , wherein the formulation comprises at least 25% by weight of purified CBD.

5. The method of claim 1 , wherein the formulation comprises at least 25% by weight of purified THC and 25% by weight of purified CBD.

6. A smokable therapeutic cannabis -based product produced according to the method of claim 1 .

7. A smokable therapeutic cannabis -based product produced according to the method of claim 2 .

8. A smokable therapeutic cannabis -based product produced according to the method of claim 3 .

9. A smokable therapeutic cannabis -based product produced according to the method of claim 4 .

10. A smokable therapeutic cannabis -based product produced according to the method of claim 5 .

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECTION TO THE CONVEYING PARTY ON COVER SHEET PREVIOUSLY RECORDED AT REEL: 047468 FRAME: 0759. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 23, 2018
From: NC3 SYSTEMS
To: CMG PARTNERS, INC.
Reel/Frame 047857/0126 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2018
From: GALVIN, BRIAN R.
To: CMG PARTNERS, INC.
Reel/Frame 047468/0759 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2018
From: THANG, MICHAEL VIET, VU; THACKER, LARRY; MARTINEZ, NELSON MIGUEL RICARDO; DURAN, AARON; STUBBLEFIELD, STEVEN
To: NC3 SYSTEMS
Reel/Frame 045627/0615 →
Cited By (3)
US 1,089,340 US 12,208,456 US 12,349,723